



4-yl-(C₁-C₄)alkyl, phosphonooxy(C₁-C₄)alkyl, 2-(phosphonooxy-(C₁-C₄)alkyl)-phenyl, (2-(phosphonooxy)-phenyl)-(C₁-C₄)alkyl (especially 2-(2-(phosphonooxy)phenyl)ethyl) or [2-(phosphonooxy-(C₁-C₄)alkyl)-phenyl]-(C₁-C₄)alkyl, or, when M is M^B or M^C, R² represents PO₃H₂, SO₃H, phosphonooxymethyl or the group L^{2BC} represented below



5 wherein R^{2BC} represents (C₁-C₄)alkylamino(C₁-C₄)alkyl, [di(C₁-C₄)alkylamino](C₁-C₄)alkyl, morpholin-4-yl-(C₁-C₄)alkyl, phosphonooxy(C₁-C₄)alkyl, phosphonooxymethoxy, 2-(phosphonooxy-(C₁-C₄)alkyl)-phenyl, (2-(phosphonooxy)-phenyl)-(C₁-C₄)alkyl (especially 2-(2-(phosphonooxy)phenyl)ethyl) or [2-(phosphonooxy-(C₁-C₄)alkyl)-phenyl]-(C₁-C₄)alkyl,
10 or R² represents H and R¹ represents PO₃H₂, SO₃H, phosphonooxymethyl or the group L¹ represented below



wherein R^{1A} represents (C₁-C₄)alkylamino(C₁-C₄)alkyl, [di(C₁-C₄)alkylamino](C₁-C₄)alkyl, morpholin-4-yl-(C₁-C₄)alkyl,
15 phosphonooxy(C₁-C₄)alkyl, phosphonooxymethoxy, 2-(phosphonooxy-(C₁-C₄)alkyl)-phenyl, (2-(phosphonooxy)-phenyl)-(C₁-C₄)alkyl (especially 2-(2-(phosphonooxy)phenyl)ethyl) or [2-(phosphonooxy-(C₁-C₄)alkyl)-phenyl]-(C₁-C₄)alkyl;

it being understood that the molecule is always such that its R² group is attached to the oxygen atom of its M^A, M^B and M^C group;

and to salts (in particular pharmaceutically acceptable salts) of compounds of formula I.

- (R)-(1-((2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)buta-1,3-diyn-1-yl)cyclopropyl)methyl 3-(2-(phosphonooxy)phenyl)propanoate;
- 5 - (R)-2-(3-((4-(6-((1-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamido)oxy)-3-oxopropyl)phenyl dihydrogen phosphate;
- ((1S,2S)-2-((2-((R)-4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)buta-1,3-diyn-1-yl)cyclopropyl)methyl dihydrogen phosphate;
- 10 - ((1S,2S)-2-((2-((R)-4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)buta-1,3-diyn-1-yl)cyclopropyl)methyl 3-(2-(phosphonooxy)phenyl)propanoate;
- ((1R,2R)-1-fluoro-2-((2-((R)-4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)buta-1,3-diyn-1-yl)cyclopropyl)methyl dihydrogen phosphate;
- 15 - (R)-((4-(6-((1-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamido)oxy)phosphonic acid;
- (R)-(1-((2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)buta-1,3-diyn-1-yl)cyclopropyl)methyl hydrogen sulfate;
- 20 or a salt of this compound.

12. A compound of formula I as defined in one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, for use as a medicament.

- 25 **13.** A pharmaceutical composition containing, as active principle, a compound of formula I as defined in one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

- 14.** Use of a compound of formula I as defined in one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of a bacterial infection.
- 30

15. The use according to claim 14, which is for the prevention or treatment of a Gram-negative bacterial infection.